GLP-1s go to the Super Bowl

Ro bets big, Novo's oral Wegovy finally arrives, and Hims crosses a line with the FDA

Feb 8 • Ashwin Sharma, MD

12

1

January 2026

Consumer health apps are dead

Long live the agents

Jan 11 • Ashwin Sharma, MD

28

3

December 2025

The 5 most important ideas for 2026

Seismic shifts are underway in the GLP-1 market

Dec 29, 2025 • Ashwin Sharma, MD

26

3

Is Your Telehealth Platform Scaring Patients Away?

Design is the overlooked moat in digital health

Dec 16, 2025 • Ashwin Sharma, MD

5

November 2025

When Science Fails, and Startups Fly

Novo has cause to be disheartened, while Function Health and GLP-1 consumers in India do not

Nov 25, 2025 • Ashwin Sharma, MD

18

2

Trump's announcement shifts competition in the GLP-1 market

Who will benefit, and who won’t?

Nov 11, 2025 • Ashwin Sharma, MD

18

1

3

Why Can't Anyone Stop Compounded GLP-1s?

Because federal, legal, and private forces won't allow it

Nov 2, 2025 • Ashwin Sharma, MD

25

3

6

September 2025

What Comes After the GLP-1 Hype?

It's messy, unglamorous stuff involving patients and insurers and crystal balls for pharma

Sep 28, 2025 • Ashwin Sharma, MD

20

5

3

When GLP-1s become brain drugs

Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?

Sep 14, 2025 • Ashwin Sharma, MD

30

3

3

Why Novo Nordisk and Eli Lilly Won't Compete on Price

But they will compete on market access and launch success

Sep 1, 2025 • Ashwin Sharma, MD

21

5

7

August 2025

The $100 Billion Overreaction

how do oral GLP-1s expand the market?

Aug 24, 2025 • Ashwin Sharma, MD

17

4

Why Britain’s GLP-1 Patients Are Paying for America’s Drug Politics

1.5 million become collateral damage

Aug 17, 2025 • Ashwin Sharma, MD

12

3

1